Klotho Neurosciences Inc. Enters Strategic Partnership with AAVnerGene Inc. to Advance Gene Therapy Innovations

Reuters

2025/07/22

Klotho Neurosciences Inc. Enters Strategic Partnership with AAVnerGene Inc. to Advance Gene Therapy Innovations

Klotho Neurosciences, Inc. (NASDAQ: KLTO) has announced a strategic partnership with AAVnerGene Inc., a biotech company based in Rockville, MD, known for its advanced AAV manufacturing and tissue-targeted delivery technologies. This collaboration aims to address challenges in AAV gene therapy, including high drug costs and dose-related toxicity, by leveraging AAVnerGene's proprietary platforms. The partnership will utilize the AAVone system to reduce manufacturing costs and the ATHENA platform for efficient tissue-targeted delivery. Klotho Neurosciences plans to apply these technologies to accelerate the development of its gene therapy candidates, such as KLTO-101 for Alzheimer's and Parkinson's diseases, KLTO-202 for ALS, and KLTO-303 for aging-related conditions. The collaboration is expected to result in more affordable and innovative treatments for both rare and common neurological diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Klotho Neuroscience Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA34799) on July 22, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2553251701"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2553251701\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2553251701?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-22 22:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553251701","market":"us","top_or_hot":-1,"title":"Klotho Neurosciences Inc. Enters Strategic Partnership with AAVnerGene Inc. to Advance Gene Therapy Innovations","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Klotho Neurosciences Inc. Enters Strategic Partnership with AAVnerGene Inc. to Advance Gene Therapy Innovations\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/KLTO\">Klotho Neurosciences, Inc.</a> (NASDAQ: KLTO) has announced a strategic partnership with AAVnerGene Inc., a biotech company based in Rockville, MD, known for its advanced AAV manufacturing and tissue-targeted delivery technologies. This collaboration aims to address challenges in AAV gene therapy, including high drug costs and dose-related toxicity, by leveraging AAVnerGene's proprietary platforms. The partnership will utilize the AAVone system to reduce manufacturing costs and the ATHENA platform for efficient tissue-targeted delivery. Klotho Neurosciences plans to apply these technologies to accelerate the development of its gene therapy candidates, such as KLTO-101 for Alzheimer's and Parkinson's diseases, KLTO-202 for ALS, and KLTO-303 for aging-related conditions. The collaboration is expected to result in more affordable and innovative treatments for both rare and common neurological diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Klotho Neuroscience Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA34799) on July 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Klotho Neurosciences Inc. Enters Strategic Partnership with AAVnerGene Inc. to Advance Gene Therapy Innovations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKlotho Neurosciences Inc. Enters Strategic Partnership with AAVnerGene Inc. to Advance Gene Therapy Innovations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-22 22:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Klotho Neurosciences Inc. Enters Strategic Partnership with AAVnerGene Inc. to Advance Gene Therapy Innovations\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/KLTO\">Klotho Neurosciences, Inc.</a> (NASDAQ: KLTO) has announced a strategic partnership with AAVnerGene Inc., a biotech company based in Rockville, MD, known for its advanced AAV manufacturing and tissue-targeted delivery technologies. This collaboration aims to address challenges in AAV gene therapy, including high drug costs and dose-related toxicity, by leveraging AAVnerGene's proprietary platforms. The partnership will utilize the AAVone system to reduce manufacturing costs and the ATHENA platform for efficient tissue-targeted delivery. Klotho Neurosciences plans to apply these technologies to accelerate the development of its gene therapy candidates, such as KLTO-101 for Alzheimer's and Parkinson's diseases, KLTO-202 for ALS, and KLTO-303 for aging-related conditions. The collaboration is expected to result in more affordable and innovative treatments for both rare and common neurological diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Klotho Neuroscience Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA34799) on July 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250722:nNDL1BwLvn:1","article_id":"2553251701","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553251701","pubTimestamp":1753194104,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Klotho Neurosciences, Inc.  has announced a strategic partnership with AAVnerGene Inc., a biotech company based in Rockville, MD, known for its advanced AAV manufacturing and tissue-targeted delivery technologies. This collaboration aims to address challenges in AAV gene therapy, including high drug costs and dose-related toxicity, by leveraging AAVnerGene's proprietary platforms. The partnership will utilize the AAVone system to reduce manufacturing costs and the ATHENA platform for efficient tissue-targeted delivery. Klotho Neurosciences plans to apply these technologies to accelerate the development of its gene therapy candidates, such as KLTO-101 for Alzheimer's and Parkinson's diseases, KLTO-202 for ALS, and KLTO-303 for aging-related conditions. The collaboration is expected to result in more affordable and innovative treatments for both rare and common neurological diseases.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","KLTO":"Klotho Neurosciences, Inc."},"translate_title":"Klotho Neurosciences Inc.与AAVnerGene Inc.建立战略合作伙伴关系，推进基因治疗创新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KLTO":0.9},"content_text":"Klotho Neurosciences Inc. Enters Strategic Partnership with AAVnerGene Inc. to Advance Gene Therapy Innovations\n    \n\nKlotho Neurosciences, Inc. (NASDAQ: KLTO) has announced a strategic partnership with AAVnerGene Inc., a biotech company based in Rockville, MD, known for its advanced AAV manufacturing and tissue-targeted delivery technologies. This collaboration aims to address challenges in AAV gene therapy, including high drug costs and dose-related toxicity, by leveraging AAVnerGene's proprietary platforms. The partnership will utilize the AAVone system to reduce manufacturing costs and the ATHENA platform for efficient tissue-targeted delivery. Klotho Neurosciences plans to apply these technologies to accelerate the development of its gene therapy candidates, such as KLTO-101 for Alzheimer's and Parkinson's diseases, KLTO-202 for ALS, and KLTO-303 for aging-related conditions. The collaboration is expected to result in more affordable and innovative treatments for both rare and common neurological diseases.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Klotho Neuroscience Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA34799) on July 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}